August 2017

HelixBind awarded a $2.0M Phase II SBIR from the National Institutes of Health (NIH) to further development of a culture-free, sample-to-answer test for detecting and identifying microbial pathogens prevalent in neonatal sepsis.

Ibriz Moonim
April 2017

USPTO issues HelixBind patent US 14/402,028 covering methods and compositions of matter for diagnosing sepsis

Ibriz Moonim
August 2016

HelixBind awarded a $2.4M Direct-to-Phase II SBIR from the National Institutes of Health (NIH) to automate its sample-to-answer test for discriminating among bacterial pathogens

Ibriz Moonim
March 2016

HelixBind published its work, completed in collaboration with Tufts Medical Center and Sloan Memorial Kettering Cancer Center demonstrating successful implementation of its novel sample-to-answer Core Pathogen Identification (C/PID) platform for identifying bloodstream infections directly from patient specimens in under 2.5 hours. For more information:
http://mbio.asm.org/content//7/2/e00345-16.full

 

Ibriz Moonim
September 2015

HelixBind awarded a $300k Phase I SBIR from the National Institutes of Health (NIH) to develop a sample-to-answer test capable of classifying different infections prevalent in neonatal sepsis

 

Ibriz Moonim
August 2015

Based on its successful Phase I results, HelixBind awarded a follow-on Phase II SBIR in the amount of $1.5M from the National Institutes of Health (NIH) to automated its sample-to-answer test for discriminating among fungal pathogens

Ibriz Moonim
August 2014

HelixBind awarded a $300k Phase I SBIR from the National Institutes of Health (NIH) to develop a sample-to-answer artificial nucleic acid probe based technology for discriminating among fungal pathogens common in bloodstream infections.

 

Ibriz Moonim
January 2014

Based on its successful Phase I results, HelixBind awarded a follow on $60k Phase IB for extending it artificial nucleic acid probe based technology for discriminating among Staphylococci.

Ibriz Moonim
August 2013

HelixBind awarded a $178k Phase I SBIR from National Institutes of Health (NIH) to develop a novel dipstick test for discriminating among Helicobacter species for use in the research setting.

Ibriz Moonim
June 2013

HelixBind awarded a $150k Phase I SBIR from the National Science Foundation (NSF) to develop an artificial nucleic acid probe based technology for discriminating among Enterococci.

Ibriz Moonim